ARQT Q4 2024 Earnings — Arcutis Biotherapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ARQTArcutis Biotherapeutics, Inc.

$3B

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$71M+427.6% YoY

Gross Profit

$64M90.3% margin

Operating Income

-$8M-10.7% margin

Net Income

-$11M-15.1% margin

EPS (Diluted)

$-0.09

QoQ Revenue Growth

+59.4%

Cash Flow

Operating Cash Flow

-$748,000

Free Cash Flow

-$6M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$349M

Total Liabilities

$191M

Stockholders' Equity

$158M

Cash & Equivalents

$71M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$71M	$14M	+427.6%
Gross Profit	$64M	$11M	+471.4%
Operating Income	-$8M	-$61M	+87.5%
Net Income	-$11M	-$66M	+83.7%